Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

Displaying Fel d1 on virus-like particles prevents reactogenicity despite greatly enhanced immunogenicity: a novel therapy for cat allergy.

Schmitz N, Dietmeier K, Bauer M, Maudrich M, Utzinger S, Muntwiler S, Saudan P, Bachmann MF.

J Exp Med. 2009 Aug 31;206(9):1941-55. doi: 10.1084/jem.20090199. Epub 2009 Aug 10.

2.
3.

Mechanisms of allergen-specific desensitization.

Uermösi C, Beerli RR, Bauer M, Manolova V, Dietmeier K, Buser RB, Kündig TM, Saudan P, Bachmann MF.

J Allergy Clin Immunol. 2010 Aug;126(2):375-83. doi: 10.1016/j.jaci.2010.05.040. Epub 2010 Jul 10.

PMID:
20624641
4.

A chimeric human-cat fusion protein blocks cat-induced allergy.

Zhu D, Kepley CL, Zhang K, Terada T, Yamada T, Saxon A.

Nat Med. 2005 Apr;11(4):446-9. Epub 2005 Mar 27.

5.

Hypoallergenic derivatives of Fel d 1 obtained by rational reassembly for allergy vaccination and tolerance induction.

Curin M, Weber M, Thalhamer T, Swoboda I, Focke-Tejkl M, Blatt K, Valent P, Marth K, Garmatiuk T, Grönlund H, Thalhamer J, Spitzauer S, Valenta R.

Clin Exp Allergy. 2014 Jun;44(6):882-94. doi: 10.1111/cea.12294.

6.

Covalent coupling of vitamin D3 to the major cat allergen Fel d 1 improves the effects of allergen-specific immunotherapy in a mouse model for cat allergy.

Grundström J, Neimert-Andersson T, Kemi C, Nilsson OB, Saarne T, Andersson M, van Hage M, Gafvelin G.

Int Arch Allergy Immunol. 2012;157(2):136-46. doi: 10.1159/000327546. Epub 2011 Oct 5.

PMID:
21985799
7.

Human T and B cell immune responses to Fel d 1 in cat-allergic and non-cat-allergic subjects.

Mark PG, Segal DB, Dallaire ML, Garman RD.

Clin Exp Allergy. 1996 Nov;26(11):1316-28.

PMID:
8955581
8.

The major cat allergen, Fel d 1, in diagnosis and therapy.

Grönlund H, Saarne T, Gafvelin G, van Hage M.

Int Arch Allergy Immunol. 2010;151(4):265-74. doi: 10.1159/000250435. Epub 2009 Oct 22. Review.

9.

IgG-mediated down-regulation of IgE bound to mast cells: a potential novel mechanism of allergen-specific desensitization.

Uermösi C, Zabel F, Manolova V, Bauer M, Beerli RR, Senti G, Kündig TM, Saudan P, Bachmann MF.

Allergy. 2014 Mar;69(3):338-47. doi: 10.1111/all.12327. Epub 2013 Dec 19. Erratum in: Allergy. 2014 Aug;69(8):1118.

10.

Targeting the MHC class II pathway of antigen presentation enhances immunogenicity and safety of allergen immunotherapy.

Martínez-Gómez JM, Johansen P, Rose H, Steiner M, Senti G, Rhyner C, Crameri R, Kündig TM.

Allergy. 2009 Jan;64(1):172-8. doi: 10.1111/j.1398-9995.2008.01812.x. Epub 2008 Nov 28.

11.

The effect of endotoxin on the production of IgE, IgG1 and IgG2a antibodies against the cat allergen Fel d 1 in mice.

Ormstad H, Groeng EC, Duffort O, Løvik M.

Toxicology. 2003 Jun 30;188(2-3):309-18.

PMID:
12767700
12.

Identification and characterization of major cat allergen Fel d 1 mimotopes on filamentous phage carriers.

Luzar J, Molek P, Šilar M, Korošec P, Košnik M, Štrukelj B, Lunder M.

Mol Immunol. 2016 Mar;71:176-83. doi: 10.1016/j.molimm.2016.02.004. Epub 2016 Feb 21.

PMID:
26908079
13.

High prevalence of sensitization to cat allergen among Japanese children with asthma, living without cats.

Ichikawa K, Iwasaki E, Baba M, Chapman MD.

Clin Exp Allergy. 1999 Jun;29(6):754-61.

PMID:
10336590
14.

Chimeric human fcgamma-allergen fusion proteins in the prevention of allergy.

Zhang K, Zhu D, Kepley C, Terada T, Saxon A.

Immunol Allergy Clin North Am. 2007 Feb;27(1):93-103. Review.

15.

A hypoallergenic cat vaccine based on Fel d 1-derived peptides fused to hepatitis B PreS.

Niespodziana K, Focke-Tejkl M, Linhart B, Civaj V, Blatt K, Valent P, van Hage M, Grönlund H, Valenta R.

J Allergy Clin Immunol. 2011 Jun;127(6):1562-70.e6. doi: 10.1016/j.jaci.2011.02.004. Epub 2011 Mar 16.

PMID:
21411130
16.

In vitro evolution of allergy vaccine candidates, with maintained structure, but reduced B cell and T cell activation capacity.

Nilsson OB, Adedoyin J, Rhyner C, Neimert-Andersson T, Grundström J, Berndt KD, Crameri R, Grönlund H.

PLoS One. 2011;6(9):e24558. doi: 10.1371/journal.pone.0024558. Epub 2011 Sep 13.

17.

Der p 1 peptide on virus-like particles is safe and highly immunogenic in healthy adults.

Kündig TM, Senti G, Schnetzler G, Wolf C, Prinz Vavricka BM, Fulurija A, Hennecke F, Sladko K, Jennings GT, Bachmann MF.

J Allergy Clin Immunol. 2006 Jun;117(6):1470-6. Epub 2006 Apr 27.

PMID:
16751015
18.

The safety and efficacy of ALLERVAX CAT in cat allergic patients.

Maguire P, Nicodemus C, Robinson D, Aaronson D, Umetsu DT.

Clin Immunol. 1999 Dec;93(3):222-31.

PMID:
10600332
19.

Rational design of hypoallergens applied to the major cat allergen Fel d 1.

Saarne T, Kaiser L, Grönlund H, Rasool O, Gafvelin G, van Hage-Hamsten M.

Clin Exp Allergy. 2005 May;35(5):657-63.

PMID:
15898990
20.

Allergen-specific immunotherapy with a monophosphoryl lipid A-adjuvanted vaccine: reduced seasonally boosted immunoglobulin E production and inhibition of basophil histamine release by therapy-induced blocking antibodies.

Mothes N, Heinzkill M, Drachenberg KJ, Sperr WR, Krauth MT, Majlesi Y, Semper H, Valent P, Niederberger V, Kraft D, Valenta R.

Clin Exp Allergy. 2003 Sep;33(9):1198-208.

PMID:
12956739
Items per page

Supplemental Content

Write to the Help Desk